Nicholas DeGennaro - Vivos Therapeutics Senior Division
| VVOS Stock | USD 3.38 0.18 5.62% |
Executive
Nicholas DeGennaro is Senior Division of Vivos Therapeutics
| Address | 7921 Southpark Plaza, Littleton, CO, United States, 80120 |
| Phone | 844 672 4357 |
| Web | https://www.vivos.com |
Vivos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.57) % which means that it has lost $0.57 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8496) %, meaning that it created substantial loss on money invested by shareholders. Vivos Therapeutics' management efficiency ratios could be used to measure how well Vivos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.91 in 2024. Return On Capital Employed is likely to gain to -4.78 in 2024. At this time, Vivos Therapeutics' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 27 M in 2024, whereas Total Current Assets are likely to drop slightly above 2.3 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lindsey Harrison | NanoVibronix | N/A | |
| Sean Wirtjes | Rapid Micro Biosystems | 55 | |
| Ryan McSeveney | Bluejay Diagnostics | N/A | |
| FACC MD | Nuwellis | N/A | |
| Sean CPA | Rapid Micro Biosystems | 55 | |
| Les DeLuca | Bluejay Diagnostics | N/A | |
| Kimberly Bambach | Tivic Health Systems | 53 | |
| John Kowalczyk | Nuwellis | N/A | |
| Robert Scott | Nuwellis | 43 | |
| FACC MBA | Nuwellis | N/A | |
| Michael Wysocki | Rapid Micro Biosystems | N/A | |
| Vitaliy Epshteyn | Nuwellis | 46 | |
| Kristine Williams | Rapid Micro Biosystems | N/A | |
| Eryn Graham | Bluejay Diagnostics | N/A | |
| Lisa Wolf | Tivic Health Systems | 61 | |
| Paul Wotta | Nuwellis | 67 | |
| Deina Walsh | Bone Biologics Corp | 60 | |
| Michael CFA | Rapid Micro Biosystems | N/A | |
| Stephen CPA | NanoVibronix | 68 | |
| Amir Rippel | NanoVibronix | N/A | |
| Indranil Dey | Bluejay Diagnostics | 61 | |
Management Performance
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.57 |
Vivos Therapeutics Leadership Team
Elected by the shareholders, the Vivos Therapeutics' board of directors comprises two types of representatives: Vivos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vivos. The board's role is to monitor Vivos Therapeutics' management team and ensure that shareholders' interests are well served. Vivos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vivos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| RaeAnn Byrnes, CoFounder Services | ||
| Kirk Huntsman, Chairman CoFounder | ||
| Julie Gannon, Chief Relations | ||
| Nicholas DeGennaro, Senior Division | ||
| John Ballard, Senior Technology | ||
| Ruth Hembree, Senior Services | ||
| Todd Huntsman, CoFounder Technology | ||
| Stephanie Huebner, Senior Integration | ||
| Susan McCullough, CoFounder Operations | ||
| Bradford Amman, Treasurer CFO |
Vivos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vivos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | (0.86) % | ||||
| Operating Margin | (0.48) % | ||||
| Current Valuation | 10.8 M | ||||
| Shares Outstanding | 4.84 M | ||||
| Shares Owned By Insiders | 1.51 % | ||||
| Shares Owned By Institutions | 13.72 % | ||||
| Number Of Shares Shorted | 95.09 K | ||||
| Price To Book | 2.02 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.